BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carranza-Naval MJ, Del Marco A, Hierro-Bujalance C, Alves-Martinez P, Infante-Garcia C, Vargas-Soria M, Herrera M, Barba-Cordoba B, Atienza-Navarro I, Lubian-Lopez S, Garcia-Alloza M. Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer's Disease and Type 2 Diabetes. Front Aging Neurosci 2021;13:741923. [PMID: 34975451 DOI: 10.3389/fnagi.2021.741923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Vargas-Soria M, García-Alloza M, Corraliza-Gómez M. Effects of diabetes on microglial physiology: a systematic review of in vitro, preclinical and clinical studies. J Neuroinflammation 2023;20:57. [PMID: 36869375 DOI: 10.1186/s12974-023-02740-x] [Reference Citation Analysis]
2 Meng X, Zhang Y, Li Z, Ma G, Zhang X, Zhang D, Cao W, Wang S, Cai Q, Cui P, Huang G. Increasing brain glucose uptake by Gypenoside LXXV ameliorates cognitive deficits in a mouse model of diabetic Alzheimer's disease. Phytother Res 2023;37:611-26. [PMID: 36325883 DOI: 10.1002/ptr.7639] [Reference Citation Analysis]
3 Woodfield A, Gonzales T, Helmerhorst E, Laws S, Newsholme P, Porter T, Verdile G. Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer's Disease. Int J Mol Sci 2022;23. [PMID: 36555450 DOI: 10.3390/ijms232415811] [Reference Citation Analysis]
4 Du H, Meng X, Yao Y, Xu J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease. Front Endocrinol (Lausanne) 2022;13:1033479. [PMID: 36465634 DOI: 10.3389/fendo.2022.1033479] [Reference Citation Analysis]
5 Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 2022;239:108277. [DOI: 10.1016/j.pharmthera.2022.108277] [Reference Citation Analysis]
6 Diz-chaves Y, Mastoor Z, Spuch C, González-matías LC, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. IJMS 2022;23:9583. [DOI: 10.3390/ijms23179583] [Reference Citation Analysis]
7 Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A. GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells 2022;11:2023. [DOI: 10.3390/cells11132023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Wu CY, Shapiro L, Ouk M, MacIntosh BJ, Black SE, Shah BR, Swardfager W. Glucose-lowering drugs, cognition, and dementia: The clinical evidence. Neurosci Biobehav Rev 2022;137:104654. [PMID: 35398114 DOI: 10.1016/j.neubiorev.2022.104654] [Reference Citation Analysis]
9 Cheng D, Yang S, Zhao X, Wang G. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases. Drug Des Devel Ther 2022;16:665-84. [PMID: 35340338 DOI: 10.2147/DDDT.S348055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]